Next-generation HIV immunotherapy: TCR technology
Engineered T-cell therapy that targets hidden HIV-infected cells using HLA-E recognition, offering a universal, next-generation immunotherapy with potential for long-term viral control or cure.
Our breakthrough technology harnesses the body’s immune power to fight HIV at its source.
Applications: T cell receptor (TCR) therapy, Engineered T cells, HLA-E restricted immunity, HIV-1 treatment
| Features | Benefits |
|---|---|
| Smart HIV Targeting | Our T-cell receptors (TCRs) are designed to recognise hidden HIV fragments presented by a unique immune molecule (HLA-E). This helps overcome HIV’s ability to hide and mutate, offering broader protection across patients |
| Precision-Engineered Receptors | Each TCR is built from well-defined genetic sequences, ensuring consistent quality, predictable performance, and easier regulatory approval |
| Gene-Based Delivery | We use advanced DNA or RNA vectors to insert these TCRs into immune cells. This allows efficient, scalable manufacturing of patient-ready cell therapies |
| Engineered Immune Cells | T cells equipped with our TCRs can seek out and destroy HIV-infected cells—potentially leading to long-term viral control or even functional cure |
| Transformative HIV Treatment Potential | Designed to work alongside or beyond antiretroviral therapy (ART), this approach could redefine how HIV is managed and move us closer to ending the epidemic |
Awaiting patent and Available For
- Co-development
- Consulting
- Licensing